D-Plus Hemolytic Uremic Syndrome Overview

Save information for later
Sign Up

Learn About D-Plus Hemolytic Uremic Syndrome

What is the definition of D-Plus Hemolytic Uremic Syndrome?
D-plus (diarrhea positive) hemolytic uremic syndrome, also known as STEC hemolytic uremic syndrome, is a rare disease that affects children between one and ten years old which is characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia). D-plus hemolytic uremic syndrome develops after certain bacterial infections, such as Escherichia. coli (E. coli) that cause diarrhea.
What are the symptoms of D-Plus Hemolytic Uremic Syndrome?
Symptoms of D-plus hemolytic uremic syndrome can be mild or severe and usually appear after an illness that is characterized by fever, abdominal cramps and pain, nausea, vomiting, and bloody diarrhea (gastroenteritis). Symptoms of D-plus hemolytic uremic syndrome may include paleness, irritability, weakness, reduced urinary output or no urine, lethargy, acute kidney injury, chronic kidney disease, protein in the urine, unexplained bruising, nosebleeds, high blood pressure, gallstones, neurological deficits, confusion, partial paralysis, seizures, coma, pancreatitis, and diabetes mellitus.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Plus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous fluid and nutrition replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplantation.
Who are the top D-Plus Hemolytic Uremic Syndrome Local Doctors?
Experienced in D-Plus Hemolytic Uremic Syndrome
Dr. Missak Haigentz
Oncology | Hematology
Experienced in D-Plus Hemolytic Uremic Syndrome
Dr. Missak Haigentz
Oncology | Hematology

Rutgers Health-Rwj Scleroderma Program

195 Little Albany St, 
New Brunswick, NJ 
 (9.5 mi)
732-235-2465
Languages Spoken:
English
See accepted insurances

Missak Haigentz is an Oncologist and a Hematologist in New Brunswick, New Jersey. Dr. Haigentz and is rated as an Experienced provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, and Laryngeal Cancer.

Advanced in D-Plus Hemolytic Uremic Syndrome
Dr. Amanda D. Kaveney
Hematology Oncology | Hematology | Oncology
Advanced in D-Plus Hemolytic Uremic Syndrome
Dr. Amanda D. Kaveney
Hematology Oncology | Hematology | Oncology

Rutgers Health-Rwj Scleroderma Program

125 Paterson St, 
New Brunswick, NJ 
 (9.5 mi)
732-235-7223
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amanda Kaveney is a Hematologist Oncology specialist and a Hematologist in New Brunswick, New Jersey. Dr. Kaveney has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. Her top areas of expertise are Shwartzman Phenomenon, Glanzmann Thrombasthenia, Gray Platelet Syndrome, and Platelet Storage Pool Deficiency.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in D-Plus Hemolytic Uremic Syndrome
Dr. Shuang A. Guo
Hematology Oncology | Oncology | Hematology
Experienced in D-Plus Hemolytic Uremic Syndrome
Dr. Shuang A. Guo
Hematology Oncology | Oncology | Hematology

Rutgers Health-Rwj Scleroderma Program

125 Paterson St, 
New Brunswick, NJ 
 (9.5 mi)
732-235-7223
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shuang Guo is a Hematologist Oncology specialist and an Oncologist in New Brunswick, New Jersey. Dr. Guo and is rated as an Experienced provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. Her top areas of expertise are Thrombocytopenia, Sickle Cell Disease, Pulmonary Embolism, and Venous Thromboembolism (VTE).

View All Doctors
What are the latest D-Plus Hemolytic Uremic Syndrome Clinical Trials?
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Biological, Other
Study Phase: Phase 3

Summary: The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Who is this study for: Patients with Atypical Hemolytic Uremic Syndrome
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Crovalimab
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

View All Clinical Trials